Scandion Oncology: Approval to expand PANTAX phase Ib into Germany - Redeye

Redeye supports Scandion receiving approval to expand PANTAX phase Ib to Germany. Today’s news reassures us that Scandion will complete PANTAX phase Ib in time, and we believe it opens the possibility for further clinical trials in Germany.

Länk till analysen i sin helhet: https://www.redeye.se/research/819711/scandion-oncology-approval-to-expand-pantax-phase-ib-into-germany?utm_source=finwire&utm_medium=RSS